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Acute renal failure (ARF) severely worsens prognosis of hospitalized patients. The most frequent cause of intrarenal ARF is
transient or prolonged renal hypoperfusion (ischemia). Ischemia primarily aﬀects the function and structure of tubular epithelial
cells, which, in severe cases, is characterized by epithelial cell necrosis. Nevertheless, ischemia does not exclusively lead to
alterations of epithelial cells but also causes interstitial inﬂammation and interstitial microvasculopathy. Both inﬂammation
and microvasculopathy are particularly important in terms of postischemic kidney repair. Postischemic microvasculopathy is
characterized by endothelial cell swelling with subsequent microvascular occlusion. Thus, reperfusion is inhibited (no-reﬂow
phenomenon). Such endothelial cell dysfunction oﬀers new therapeutic perspectives in ischemic ARF. Newer observations point
towards the role of the so-called endothelial progenitor cells (EPCs) in the treatment of ARF. Systemic administration of EPCs
to mice with bilateral renal ischemia mitigates postischemic endothelial cell dysfunction and protects animals from acute renal
failure.
1.Introduction
Acute renal failure (ARF) severely worsens prognosis of hos-
pitalizedpatients.Approximately1–5%ofallpatientstreated
in the hospital develop ARF [1]. The clinical signiﬁcance of
ARF results from its high mortality, which still today ranges
from 30 to 70% [2]. ARF is categorized depending on its
primary cause. Prerenal failure results from transient renal
hypoperfusion. It is a functional response of a structurally
intact kidney to hypoperfusion [3]. While postrenal ARF is
caused by urinary tract obstruction with or without subse-
quent damage of renal tissue, intrinsic or intrarenal ARF is
caused by diseases that either aﬀect the glomeruli, the vas-
culature, the interstitium, or the tubules. The diﬀerence
betweenprerenalandintrarenalfailureduetohypoperfusion
lies in the presence of structural tubular damage in the latter.
The most frequent cause of intrarenal ARF in hospitalized
patients is transient or prolonged renal hypoperfusion (is-
chemia reperfusion injury—IRI) [4–6]. Renal IRI is of par-
ticular importance in the setting of kidney transplantation
[7]. Ischemia primarily aﬀects the function and structure of
tubularepithelialcells,which,inseverecases,ischaracterized
by epithelial cell necrosis [8]. Nevertheless, IRI does not
exclusively lead to alterations of epithelial cell function and
structure but also causes interstitial inﬂammation and in-
terstitial microvasculopathy (Figure 1). These alterations
can delay restoration of renal function which potentially
worsens prognosis of patients with ischemic ARF [3]. Postis-
chemic microvasculopathy is characterized by endothelial
cell swelling, leading to prolonged ischemia even if the pri-
mary cause of hypoperfusion has been eliminated [9, 10].
Such no-reﬂow phenomenon has also been described in other
organs [11]. In recent years, it has become more and more
evidentthatbytargetingpostischemicrenalmicrovasculopa-
thy, kidney function can partially or completely be preserved
[9, 10]. First investigations were performed by the group of
Goligorsky [12]. Immunoincompetent rats with renal IRI
were injected with mature endothelial cells from humans
(human umbilical vein endothelial cells—HUVECs). Ani-
mals were not only protected from ARF, but histological2 Journal of Transplantation

















Figure 1: Acute ischemic renal failure is characterized by tubular epithelial cell dysfunction and damage. Postischemic restoration of kidney
function and structure critically depends on both interstitial inﬂammation and peritubular microvasculopathy. The latter causes ongoing
renal hypoperfusion even if ischemia has been corrected.
analysis showed direct incorporation of HUVECs into the
endothelial cell layer within the renal microvasculature [12].
In subsequent years, comparable therapeutic eﬀects were
demonstrated for so-called endothelial progenitor cells
(EPCs). In this paper, we will summarize the current knowl-
edge on postischemic interstitial inﬂammation and micro-
vasculopathy, and we will discuss therapeutic strategies to
target microvasculopathy in acute ischemic renal failure.
2.InterstitialInﬂammation
During the last 15 years, our knowledge of postischemic
inﬂammation in the kidney has signiﬁcantly been increased.
The inﬂammatory process is initiated by both endothelial
and tubular cell dysfunction. A number of diﬀerent proin-
ﬂammatory/immunomodulatory cytokines, such as IL-1, -6,
and -8, TGF-β,T N F - α, and MCP-1 (monocyte chemoattrac-
tant protein-1), are released into the renal tissue and the
circulation, respectively [13, 14]. Serum levels of IL-6 have
been shown to indicate a higher risk of death in patients with
acute kidney injury (AKI) [15]. Recently, Toll-like receptor 4
(TLR 4) has been shown to play an essential role in postis-
chemic renal IL-6 production [16]. In this study, leukocytes
fromTLR4knockoutmice(TLR4(−/−))inﬁltratedkidneys
of TLR 4-expressing animals (TLR 4 (+/+)), but there
was almost no impairment of renal function. In addition,
only leukocytes from TLR 4 (+/+) mice produced IL-6 in
response to high-mobility group protein B1 (HMGB1). The
renoprotective consequences of TLR 4 inactivation have also
been documented by Zhang and colleagues [17]. Earlier
studies showed that TLR 2 represents an important regulator
of the proinﬂammatory response as well. Renal tubular
epithelial cells displayed increased TLR 2 expression after
acute ischemia, and TLR 2 inactivation protected mice from
AKI [18]. TLR 2 (−/−) mice did not only show decreased
intrarenal expression of MCP-1, TNF-α, IL-6, and IL-1, but
tissue inﬁltration by neutrophils was also markedly reduced.
Postischemic tissue inﬁltration by certain populations of
inﬂammatory cells is a hallmark in renal IRI. Neutrophils,
macrophages, natural killer cells, and diﬀerent subtypes of T
cells home to the interstitial space where they modulate the
inﬂammatoryresponse[3,19–24].Theearliestpopulationof
cellsthataccumulatewithinperitubularcapillaries,theinter-
stitium, and to some extent within tubules are neutrophils
[3]. Nevertheless, the clinical signiﬁcance of neutrophil
inﬁltration can be doubted or at least remains a matter of
debate, although blockade of neutrophil function partially
protectsanimalsfromAKIinsomemodels[20].Depletionof
macrophagesalsoamelioratesrenalfunction[21]inischemic
AKI. However, macrophage activity critically depends on theJournal of Transplantation 3
function of T cells. The data on the role of T cells in renal IRI
are conﬂicting. Nu/nu-mice, which neither produce CD4+
nor CD8+ T cells, displayed higher ischemia tolerance as
compared to wild-type animals [23]. Selective reconstitution
of CD4+ T cells signiﬁcantly worsened renal function after
ischemia. Comparable renoprotective eﬀects were observed
in Rag-1 knockout (KO) mice. Such animals have small lym-
phoid organs that do not contain mature B and T cells [25].
The recombination activating genes-1 and -2 are required
for somatic assembly of both the B- and T-cell receptors
[26]. Ischemia protection in Rag-1 KO mice was reversed
if the animals were adoptively transferred with WT CD4+
cells. These eﬀects critically depended on the cells’ ability
to produce Interferon-γ [24]. Nevertheless, it is doubtable
that CD4+ T cells exclusively mediate deleterious eﬀects
on renal function. Recently, Lee and colleagues investigated
the role of CD4+/CD25+ (regulatory) T cells in cisplatin-
induced AKI [27]. Nu/nu-mice showed increased survival,
reduced tubular epithelial cell damage, and decreased tissue
levels of TNF-α after administration of CD4+/CD25+ T cells.
Comparable data were published by Yokota and colleagues
[28]. Depending on their respective phenotype, CD4+ Tc e l l s
were shown to either act protective or deleterious in the
setting of IRI. Such modulatory actions partly depended on
the balance between INF-γ and IL-4 production [28]. In
summary, the role of T cells in AKI is rather complex, and
it can be assumed that individual biological properties of
the diﬀerent subsets of T-cells are fundamentally important
in the process of kidney repair after ischemia. While T cell-
mediated eﬀects on postischemic kidney repair and function
seem to require the presence of the cells in the kidney, this is
not mandatory with B cells. B-cell depletion has been shown
to partly protect from ischemia-induced structural damage,
although neutrophil and T-cell inﬁltrates were not dimin-
ished [29]. Interestingly, susceptibility to ischemia could
be reestablished by serum transfer from wild-type animals.
Transfer of B cells in contrast was not associated with de-
creased ischemia tolerance. Whether these eﬀects were exclu-
sively related to antibodies remains unclear [29].
NaturalkillerT-cells(NKTcells)belongtotheTcellfam-
i l yo fl y m p h o c y t e s .T h e ye x p r e s sc e l ls u r f a c em a r k e rm o l e -
cules of conventional T cells, but in addition they are positive
forNK1.1,alsoknownasNKR-P1.9(naturalkillercellrecep-
torP1.9)[30,31].TheT-cellreceptorofNKTcellsrecognizes
glycolipids presented by the class I-like molecule CD1d [30].
NKT cells can produce a diverse group of cytokines in re-
sponse to antigen recognition which ampliﬁes the activity of
dendritic cells, conventional T cells, regulatory T cells, other
NKT cells, and B cells, respectively [30]. In an elegant study,
Li and colleagues [32] investigated the role of NKT cells in
murine IRI. Renal ischemia of 30 minutes was followed by
NKT cell and neutrophil accumulation in the kidney and
by signiﬁcantly increased IFN-γ tissue levels. Inhibition of
NKT cell activity by cell depletion decreased numbers of
IFN-producing neutrophils in the kidney and protected mice
from AKI [32].
Another hallmark of IRI-associated inﬂammation is acti-
vation of the complement system [3, 33]. The complement
cascade is represented by more than 30 plasma proteins
which predominantly are produced by the liver. They are
critically involved in the innate immune response. Com-
plement activation can occur by binding of C1q to the Fc
fragment of antibodies (classical pathway) and, on the other
hand, the cascade is permanently activated by spontaneous
degradation of complement factor C3 (alternative pathway)
[34]. Factor C5a has been shown to play an important role
in IRI-induced kidney inﬂammation [33]. As a matter of
fact, the C5a receptor is expressed by tubular epithelial cells
and by certain interstitial macrophages, respectively [35]. IRI
increases C5a receptor expression in the proximal tubule
[36]. C5a acts as potent chemoattractant which results in
the recruitment of neutrophils, monocytes, and T cells [3].
Administration of anti C5a mAB has been shown to block
neutrophilandmacrophageinvasionafterrenalischemiaand
to protect mice from renal dysfunction [36]. Although com-
plement activation in murine IRI is predominantly mediated
by the alternative pathway [37], a recent study identiﬁed the
classical pathway to be the essential complement activator
in human IRI [38]. Hypoxia treatment of proximal tubular
epithelial cells from humans (PTEC) induced signiﬁcant
complement activation. By using C1q-depleted serum or
by blocking C1q with antibodies, the classical pathway was
shown to be critically responsible for initiating the cascade.
Furthermore, this process was mediated by IgM which binds
to PTEC in response to hypoxia [38].
The consequences of interstitial inﬂammation for the
treatment of renal IRI are currently investigated. IL-10,
which acts as an anti-inﬂammatory mediator, protected
against ischemic AKI by inhibiting Th1 cell function [39].
Comparable renoprotective eﬀects were observed with the
administrationofanti-IL-6mAb.Thisapproachsigniﬁcantly
inhibited production of proinﬂammatory mediators and
tissueinﬁltrationbyneutrophils[40].Veryinterestingresults
are related to eﬀects of α-melanocyte-stimulating hormone
or melatonin. The hormone, also known as N-acetyl-5-
methoxytryptamine, is produced by the pineal gland, and it
is released into the circulation in a circadanic manner [41].
It had once been discussed to act as key regulator in sleep-
wake rhythm [42]. Although this concept has been modiﬁed
in recent years, the hormone has been shown to be involved
in a number of other physiological events, namely, the detox-
iﬁcation of free radicals [9]. In addition, melatonin can in-
hibit activation of proinﬂammatory genes which cause renal
injury after ischemia. In this setting, it even augments anti-
ischemic actions of erythropoietin and protects mice from
AKI-associated lung injury [43].
If such strategies will be established in human AKI one
day remains speculative at the moment, but one has to be
aware of the fact that renal IRI is neither an exclusive tubular
nor vascular disease but also a severe inﬂammatory process.
Postischemic renal inﬂammation may also contribute to mi-
crovasculopathy in IRI, which will be the topic of the next
section.
3. Microvasculopathy inRenalIRI
Microvasculopathy signiﬁcantly contributes to ongoing pos-
tischemic kidney dysfunction. Despite the fact that renal4 Journal of Transplantation
hypoperfusion mainly causes functional and structural alter-
ations of the tubular epithelium, studies performed in recent
yearspointedtowardtheroleofpostischemicendothelialcell
dysfunction (ED) in peritubular capillaries as an important
perpetuating factor of prolonged kidney malfunction [12,
44].
First evidence for the role of postischemic ED in acute
ischemic kidney injury came from studies performed in the
early 1970s [45]. Rats undergoing renal artery clamping dis-
played swelling of all cellular elements in the kidney which
causedpersistentrenalhypoperfusionevenafterreperfusion.
Swelling of endothelial cells signiﬁcantly contributed to such
no reﬂow. Extracellular ﬂuid expansion, induced by hyper-
tonic mannitol solution, partly prevented swelling of endo-
thelial cells and thus protected from (post)ischemic renal
damage. Hence, cell swelling had been identiﬁed as patho-
geneticfactorintissueischemia[46].Asamatteroffact,pos-
tischemic ED has to be considered as global cellular dysfunc-
tion syndrome, characterized, in addition to cell swelling, by
increased paracellular and transcellular endothelial perme-
ability and by increased endothelial expression of diﬀerent
types of cell adhesion molecules. Among those are P- and
E-selectin and ICAM-1, respectively. The two selectins and
ICAM-1 mediate leukocyte-endothelial interactions, a pre-
requisite for transvascular leukocyte migration. Inhibition of
the selectins and of ICAM-1 has been shown to reduce renal





Taken together, these observations pointed toward a new
therapeutic approach in ischemic AKI: targeting of postis-
chemic ED [50]. First evidence for the viability of such treat-
ment came from studies performed by the group of Golig-
orsky[12,44].Systemicinjectionsofmatureendothelialcells
from humans (HUVECs—human umbilical vein endothelial
cells) into immunoincompetent nude rats protected the
animals from ischemic kidney damage. In vivo microscopic
analysisshowedpostischemicendothelialcellswellingwithin
the peritubular capillary network, and, in addition, showed
that complete normalization of microvascular tissue perfu-
sion occurred as late as 24 hours after ischemia. In this set-
ting, systemic administration of HUVECs markedly inhib-
ited swelling of endothelial cells and promoted a faster func-
tional and structural recovery of the organ. Histologically,
injected cells had partly been incorporated into the endothe-
lial layer of small blood vessels surrounding the tubular
integrity. These studies showed for the ﬁrst time that target-
ing of postischemic ED by the administration of cells of the
endothelial lineage is a true option in the treatment of acute
ischemic kidney injury. Although such therapeutic approach
is promising, a number of questions remain. The most rele-
vant question is related to the source of cells of endothelial
origin. If endothelial-type cells are supposed to be admin-
istered in acute kidney injury, they must become available
within a short period of time. The next problem is related to
the immunological acceptance of exogenously injected cells.
In an optimal setting, cells would rapidly be isolated from
the recipient in order to become available for immediate
systemic administration if necessary. A possible alternative
may be represented by the so-called endothelial progenitor
cells (EPCs) which will be reviewed in the last section.
4.EndothelialProgenitorCells
(EPCs)inRenal IRI
EPCs were described for the ﬁrst time in 1997 [51]. Cells
expressing CD34 were isolated from human umbilical vein
blood and, after several days of culturing, systemically inject-
ed into immunoincompetent animals with ischemic lesions
of the lower extremities. This measure did not only improve
postischemic blood ﬂow, but microscopic analysis showed
direct incorporation of injected cells into the endothelial
layer of blood vessels within the reperfused tissue. For many
years, it has been assumed that EPCs are more or less exclu-
sively derived from pluripotent hematopoietic stem cells in
the bone marrow. Meanwhile, this concept has signiﬁcantly
been modiﬁed. According to the current literature on EPC
biology at least two major populations of EPCs have to be
diﬀerentiated [52–55]. The ﬁrst and by far more in detail
analyzed population is represented by so-called endothelial
cell-like cells (EC-like cells) or early endothelial outgrowth
cells (eEOCs) [9]. Early endothelial outgrowth cells develop
from hematopoietic stem cells in the bone marrow and
they express both, endothelial and hematopoietic cell marker
molecules [55]. In addition, they are capable of diﬀeren-
tiating into cells of the hematopoietic lineage. Culturing
eEOCs from mononuclear blood cells takes 5–7 days and
it has reproducibly been shown that the cells can act anti-
ischemic in diﬀerent experimental situations. A number of
studies evaluated the diagnostic and therapeutic value of
eEOCs in ischemic heart disease [56–58]. Although initial
studies by Asahara et al. [51] suggested that EPC-mediated
vascular repair results from direct cell incorporation into the
endothelial layer of small blood vessels, newer concepts favor
indirect mechanisms to be responsible for vasoprotection.
Thus, EPCs home into the postischemic tissue where they
releasediﬀerentproangiogenicmediatorssuchasVEGF(vas-
cular endothelial growth factor), HGF (hepatocyte growth
factor),andIGF-1(insulin-likegrowthfactor-1),respectively
[59]. These substances promote a faster recovery of damaged
endothelial cells [9, 60]. The second EPC-subpopulation is
represented by the so-called late endothelial outgrowth cells
(lEOCs) or endothelial colony-forming cells (ECFCs) [54, 55].
Late outgrowth endothelial cells can also be cultured from
mononuclear blood cells, but in contrast to eEOCs, they are
not capable to diﬀerentiate into cells of the hematopoietic
lineage [9]. In vitro studies showed signiﬁcantly stronger
formation of vessel-like structures with lEOCs than with
eEOCs. In a newer review paper by Yoder and Ingram [54],
it has even been questioned if lEOCs are true progenitors of
endothelial cells since they share a number of characteristics
with mature endothelial cells. The only diﬀerence between
mature endothelial cells and lEOCs lies in the higher pro-
liferative potential of the latter. Nevertheless, proangiogenic
or anti-ischemic eﬀects have been shown for both cell types,Journal of Transplantation 5
eEOCs and lEOCs. The vast majority of studies performed
over the last 14 years investigated the role of eEOCs.
Acute ischemic renal failure is characterized by severe
endothelial dysfunction [10, 12]. With regard to the promis-
ing studies by Brodsky et al. [12], the role of eEOCs in the
treatment of acute ischemic renal failure was investigated
for the ﬁrst time about 6 years ago [61]. Early endothelial
outgrowth cells were signiﬁcantly mobilized by acute kidney
ischemia and ischemic preconditioning of the animals in-
duced eEOC homing into the postischemic tissue. Mononu-
clear cells isolated from such kidneys protected recipient
animals from renal failure which was the proof-of-principle
that eEOCs can serve as therapeutic tool in iAKI. Mean-
while, diﬀerent strategies to increase renoprotective eﬀects
of eEOCs in iAKI have been established. In 2009, the sub-
stance 8-pCPT-2 -O-Me-cAMP (Epac-1 Ac) has been shown
to augment the eﬃciency of an eEOC-based therapeutic
regimen in iAKI [62]. Epac-1 Ac induced redistribution of
β1-integrins towards the plasma membrane of eEOCs which
increased eEOC homing into the renal tissue. Newer and
yet unpublished data indicate signiﬁcantly eEOC stimu-
lating eﬀects of the hormone melatonin. Melatonin-pre-
treated eEOCs showed higher renoprotective potential than
untreated cells. The responsible mechanisms were not relat-
edtoincreasedhomingofthecells,butmelatoninactedanti-
apoptotic, stimulated VEGF secretion by the cells, and
increased migration of eEOCs in vitro. In addition, super-
natant from melatonin-treated eEOCs induced faster migra-
tion of mature endothelial cells.
Together,thesedataclearlyshowthateEOCsareareliable
option to ameliorate the short-term prognosis of iAKI. Cur-
rent own investigations focus on the process of ﬁbrogenesis
afteracutekidneyischemia.Themid-tolong-termprognosis
of iAKI critically depends on the amount of postischemic
renal ﬁbrosis [63]. It has recently been shown that EPCs
inhibit renal ﬁbrogenesis in two models of chronic renal
failure [64, 65]. It seems most likely that eEOCs can be
employed as antiﬁbrotic therapeutic tool in iAKI and as a
matter of fact, ﬁrst own and also yet unpublished observa-
tions seem to conﬁrm this theory.
Nevertheless, a number of questions still need to be an-
swered before eEOCs will ﬁnally become usable for treating
patients with iAKI. The most signiﬁcant problem is still
related to the time frame which is needed for the cells to
be isolated. Further investigations will have to be performed
in order to optimize the process of cell enrichment for
therapeutic administration.
5. Conclusion
Acute ischemic renal failure (iARF) is the most frequent type
of acute renal failure in hospitalized patients. Although renal
hypoperfusion primarily aﬀects the function and structure
ofthetubularepithelium,alterationsofthemicrovasculature
and inﬂammatory processes within the interstitial space are
of particular importance with regard to postischemic resto-
ration of kidney function. Postischemic microvasculopathy,
w h i c hi ns e v e r ec a s e si sc h a r a c t e r i z e db yo b s t r u c t i o no ft h e
peritubular vasculature, can potentially serve as therapeutic
target in acute ischemic renal failure. Early endothelial out-
growth cells (eEOCs) are potent inhibitors of postischemic
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